Sessa A, Righetti M, Battini G
Nephrology and Dialysis Unit, District Hospital, Vimercate, Milan, Italy.
Minerva Urol Nefrol. 2004 Dec;56(4):329-38.
It is possible to identify renal cysts in several subjects by ultrasonography imaging techniques. Among the inherited polycystic kidney diseases we include autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic diseases such as von Hippel-Lindau disease, tuberous sclerosis complex (TSC1 and TSC2), and autosomal dominant polycystic kidney disease (ADPKD). ARPKD is a rare disease, related to PKHD1 gene, located on chromosome 6p21, that encodes a protein named polyductin/fibrocystin. Pathoanatomical features are bilateral kidney involvement with multiple microcysts, and invariably liver involvement with portal and interlobular fibrosis. A single genetic defect leads to different degrees of renal and hepatic involvement with very different phenotypes and different clinical outcome, in the same family too. ARPKD clinically may show 4 different forms: perinatal, neonatal, infantile, and juvenile. ADPKD is much more frequent (1: 400-1000 live births), and can arise from mutations in 2 different genes, named PKD1 located on chromosome 16p13.3, and PKD2 located on chromosome 4q21-23. The proteins encoded by the PKD1 and PKD2 genes are named polycystins which play crucial roles in several biologic processes. To explain the focal lesions that affected different organs and tissues the "double hit" theory has been proposed (germinal mutation plus somatic mutation on PKD1 or PKD2). Recently, biologic evidence documented the crucial role of the renal primary cilia on the formation of polycystins to induce cystogenesis. ADPKD may be clinically characterized by abdominal pain, hypertension, episodes of gross hematuria, headache, renal stones, aortic and cerebral aneurysms, mitral valve prolapse, and polycystic liver disease. ADPKD is slowly progressive disease responsible for up 10% of end stage renal failure (ESRF) in every country of the world. Male sex, PKD1 gene, episodes of gross hematuria, and the precocity and severity of hypertension play an important role in the progression of renal disease to ESRF.
通过超声成像技术可以在多个受试者中识别肾囊肿。在遗传性多囊肾病中,我们包括常染色体隐性多囊肾病(ARPKD)和常染色体显性多囊疾病,如冯·希佩尔-林道病、结节性硬化症复合体(TSC1和TSC2)以及常染色体显性多囊肾病(ADPKD)。ARPKD是一种罕见疾病,与位于6号染色体p21上的PKHD1基因相关,该基因编码一种名为多囊蛋白/纤维囊肿蛋白的蛋白质。病理解剖特征为双侧肾脏受累伴多个微囊肿,且肝脏总是受累伴门静脉和小叶间纤维化。单一基因缺陷会导致同一家庭中不同程度的肾脏和肝脏受累,伴有非常不同的表型和不同的临床结局。ARPKD临床上可能表现为4种不同形式:围产期、新生儿期、婴儿期和青少年期。ADPKD更为常见(每400 - 1000例活产中有1例),可由位于16号染色体p13.3上的PKD1和位于4号染色体q21 - 23上的PKD2这两个不同基因的突变引起。PKD1和PKD2基因编码的蛋白质名为多囊蛋白,它们在多个生物学过程中起关键作用。为了解释影响不同器官和组织的局灶性病变,有人提出了“双重打击”理论(PKD1或PKD2上的胚系突变加体细胞突变)。最近,生物学证据证明了肾初级纤毛在多囊蛋白形成以诱导囊肿形成过程中的关键作用。ADPKD的临床特征可能包括腹痛、高血压、肉眼血尿发作、头痛、肾结石、主动脉瘤和脑动脉瘤、二尖瓣脱垂以及多囊肝病。ADPKD是一种缓慢进展的疾病,在世界各国导致高达10%的终末期肾衰竭(ESRF)。男性、PKD1基因、肉眼血尿发作以及高血压的早熟和严重程度在肾病进展至ESRF过程中起重要作用。